These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33288636)

  • 1. Favipiravir and the Need for Early Ambulatory Treatment of COVID-19.
    Korman TM
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33288636
    [No Abstract]   [Full Text] [Related]  

  • 2. Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19).
    McCullough PA
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32967849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series.
    Fu D; Cao R; Zhao L; Li W; Zhong W; Wen J
    Crit Care; 2020 Sep; 24(1):578. PubMed ID: 32977854
    [No Abstract]   [Full Text] [Related]  

  • 4. A Favipiravir-induced Fever in a Patient with COVID-19.
    Kurita T; Ishida K; Muranaka E; Sasazawa H; Mito H; Yano Y; Hase R
    Intern Med; 2020; 59(22):2951-2953. PubMed ID: 33191372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comment on: Favipiravir, an antiviral for COVID-19?
    Chachaima-Mar J; Pérez-Castilla J
    J Antimicrob Chemother; 2021 Jan; 76(1):279-280. PubMed ID: 32888000
    [No Abstract]   [Full Text] [Related]  

  • 6. Comment on: Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia.
    Hashemian SM; Khoundabi B; Velayati AA
    Int Immunopharmacol; 2022 Jan; 102():107693. PubMed ID: 34217670
    [No Abstract]   [Full Text] [Related]  

  • 7. Virological and genomic analysis of SARS-CoV-2 from a favipiravir clinical trial cohort.
    Suzuki M; Imai T; Sakurai A; Komoto S; Ide T; Lim CK; Shintani A; Doi Y; Murata T
    J Infect Chemother; 2021 Sep; 27(9):1350-1356. PubMed ID: 34176716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two Cases of Severe COVID-19 Pneumonia Effectively Treated with Extracorporeal Membrane Oxygenation in Addition to Favipiravir and Corticosteroid.
    Shinoda M; Kamachi K; Ota S; Yoshimatsu L; Boku R; Yoshida Y; Hirouchi T; Shinada K; Sato T; Morikawa M; Iwata K; Matsumoto T; Shinkai M
    Intern Med; 2021; 60(1):123-130. PubMed ID: 33390469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients.
    Chen PJ; Chao CM; Lai CC
    J Infect; 2021 May; 82(5):186-230. PubMed ID: 33301818
    [No Abstract]   [Full Text] [Related]  

  • 10. Adverse events associated with nafamostat mesylate and favipiravir treatment in COVID-19 patients.
    Hifumi T; Isokawa S; Otani N; Ishimatsu S
    Crit Care; 2020 Aug; 24(1):497. PubMed ID: 32787901
    [No Abstract]   [Full Text] [Related]  

  • 11. Bilateral foot ulcers in a COVID-19 patient under favipiravir treatment.
    Hayran Y; Albayrak İD; Öcalan DT; Aktaş A
    J Cosmet Dermatol; 2021 Aug; 20(8):2390-2391. PubMed ID: 34146463
    [No Abstract]   [Full Text] [Related]  

  • 12. Alectinib, COVID-19 and favipiravir.
    Mungmunpuntipantip R; Wiwanitkit V
    J Oncol Pharm Pract; 2021 Oct; 27(7):1810. PubMed ID: 34424078
    [No Abstract]   [Full Text] [Related]  

  • 13. Favipiravir Induced Nephrotoxicity in Two Patients of COVID-19.
    Nasa P; Shrivastava P; Kulkarni A; Vijayan L; Singh A
    J Assoc Physicians India; 2021 Jan; 69(1):90. PubMed ID: 34227789
    [No Abstract]   [Full Text] [Related]  

  • 14. Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019.
    Hase R; Kurata R; Ishida K; Kurita T; Muranaka E; Mito H
    Intern Med; 2020 Sep; 59(18):2327-2329. PubMed ID: 32727996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Favipiravir as an Antiviral Agent in Coronavirus Disease 2019 (COVID-19): Same Script, Different Cast?
    Dauby N
    Clin Infect Dis; 2021 Aug; 73(3):e847-e848. PubMed ID: 33075124
    [No Abstract]   [Full Text] [Related]  

  • 16. Hematological Malignancy Patients, COVID-19, and Favipiravir.
    Mungmunpuntipantip R; Wiwanitkit V
    Turk J Haematol; 2021 Dec; 38(4):331-332. PubMed ID: 34792305
    [No Abstract]   [Full Text] [Related]  

  • 17. Favipiravir Induced Nephrotoxicity in two Patients of COVID-19.
    Nasa P; Shrivastava PK; Kulkarni A; Vijayan L; Singh A
    J Assoc Physicians India; 2021 Jun; 69(6):11-12. PubMed ID: 34472793
    [No Abstract]   [Full Text] [Related]  

  • 18. Letter to the editor on "Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial" by Udwadia et al.
    Medisetty MK; Patel A; Pujari S
    Int J Infect Dis; 2021 Apr; 105():722. PubMed ID: 33601033
    [No Abstract]   [Full Text] [Related]  

  • 19. An AGEP case due to COVİD-19 or favipiravir or enoxaparin.
    Daye M; Oltulu P
    J Cosmet Dermatol; 2022 Jan; 21(1):13-15. PubMed ID: 34826196
    [No Abstract]   [Full Text] [Related]  

  • 20. Response to the comments received on article "Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial" by Udwadia et al.
    Udwadia ZF; Barkate H; Patil S; Rangwala S; Wu W; Caracta CF; Tandon M
    Int J Infect Dis; 2021 Apr; 105():686-687. PubMed ID: 33601032
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.